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Rituximab for diffuse large B-cell lymphoma
patients: a population-based analysis
Sara Khor1,2,3,4, Jaclyn Beca1,2,3, Murray Krahn3,5,6,7,11, David Hodgson3,7,8,11, Linda Lee9, Michael Crump10,
Karen E Bremner6, Jin Luo11, Muhammad Mamdani2,7,11, Chaim M Bell7,12, Carol Sawka3,7, Scott Gavura13,
Terrence Sullivan3,7,14, Maureen Trudeau15, Stuart Peacock3,16,17 and Jeffrey S Hoch1,2,3,7,11*Abstract
Background: Current treatment of diffuse-large-B-cell lymphoma (DLBCL) includes rituximab, an expensive drug,
combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy. Economic
models have predicted rituximab plus CHOP (RCHOP) to be a cost-effective alternative to CHOP alone as first-line
treatment of DLBCL, but it remains unclear what its real-world costs and cost-effectiveness are in routine clinical
practice.
Methods: We performed a population-based retrospective cohort study from 1997 to 2007, using linked administrative
databases in Ontario, Canada, to evaluate the costs and cost-effectiveness of RCHOP compared to CHOP alone. A
historical control cohort (n = 1,099) with DLBCL who received CHOP before rituximab approval was hard-matched on
age and treatment intensity and then propensity-score matched on sex, comorbidity, and histology to 1,099 RCHOP
patients. All costs and outcomes were adjusted for censoring using the inverse probability weighting method. The
main outcome measure was incremental cost per life-year gained (LYG).
Results: Rituximab was associated with a life expectancy increase of 3.2 months over 5 years at an additional cost of
$16,298, corresponding to an incremental cost-effectiveness ratio of $61,984 (95% CI $34,087‐$135,890) per LYG. The
probability of being cost-effective was 90% if the willingness-to-pay threshold was $100,000/LYG. The cost-effectiveness
ratio was most favourable for patients less than 60 years old ($31,800/LYG) but increased to $80,600/LYG for patients
60–79 years old and $110,100/LYG for patients ≥80 years old. We found that post-market survival benefits of rituximab
are similar to or lower than those reported in clinical trials, while the costs, incremental costs and cost-effectiveness
ratios are higher than in published economic models and differ by age.
Conclusions: Our results showed that the addition of rituximab to standard CHOP chemotherapy was associated
with improvement in survival but at a higher cost, and was potentially cost-effective by standard thresholds for
patients <60 years old. However, cost-effectiveness decreased significantly with age, suggesting that rituximab
may be not as economically attractive in the very elderly on average. This has important clinical implications
regarding age-related use and funding decisions on this drug.* Correspondence: Jeffrey.hoch@utoronto.ca
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Combination chemotherapy with cyclophosphamide,
doxorubicin, vincristine, and prednisone (CHOP) is
the standard care for diffuse large B cell lymphoma
(DLBCL), an aggressive, common form of non-Hodgkin
lymphoma. In the last decade, four randomized con-
trolled trials (RCTs) and two small observational studies
demonstrated that the addition of the humanized
monoclonal antibody rituximab to this combination
(RCHOP) significantly improved the overall survival of
patients undergoing primary treatment, although very
elderly patients (≥80 years) were underrepresented
[1-7]. Our recent population-based study (n = 4,021)
showed that RCHOP was associated with a significant
increase in overall survival compared to CHOP in all
ages, including ≥80 years, without evidence of any sig-
nificant increase in serious toxicity detected [8].
However, the high cost of rituximab brings its cost-
effectiveness into question. This is problematic because
cost-effectiveness information is a critical complement
of comparative effectiveness research for producing effi-
cient care and promoting fairness; it supports clinicians’
professional commitment to fair distribution of finite re-
sources and helps health care payers and plans ensure
value for money [9,10]. Economic models comparing
RCHOP to CHOP have found RCHOP to be either a
dominant strategy [11], or a cost-effective alternative to
CHOP [12-15], but these models have relied on efficacy
findings from RCTs and required assumptions regarding
resource use since economic data were not prospectively
collected. This is particularly relevant given the repeated
demonstrations that patients who are eligible for RCTs
are not representative of the wider population expected
to use the treatment [16]. While these economic models
may be useful in informing coverage decisions, they may
not represent the true cost-effectiveness of rituximab in
practice. There remains a lack of evidence needed by
payers to assess the extent to which the innovation is
medically beneficial and financially sustainable for typ-
ical patients in routine clinical settings.
We evaluated the real-world cost-effectiveness of rituxi-
mab in patients with newly diagnosed DLBCL, using rou-
tinely collected widely available data. Our objective was to
provide an assessment of value for money and account-
ability for spending on rituximab for DLBCL in practice
from a population-based health care system’s perspective
using administrative data on real world patients.
Methods
Data sources
Our study received research ethics board approval from
St. Michael’s Hospital and Sunnybrook and Women’s
College Health Sciences Centre. All Ontario residents
are covered for medically-necessary health care througha universal government-sponsored insurance plan [17].
This retrospective cohort study used linked data from
several population-based administrative health-care da-
tabases (see Additional file 1: Table S1), and cancer spe-
cific databases (see Additional file 1: Table S2) in the
province of Ontario, Canada. Permissions were received
from the Institute for Clinical Evaluative Sciences,
Cancer Care Ontario, and the Princess Margaret
Hospital to use the data. All cost components included
in this article were fully covered by the Ontario Ministry
of Health and Long-Term Care during the study period.
All intravenous cancer drugs were administered in can-
cer centres or hospitals.
Study cohort
Rituximab was approved for public funding via the New
Drug Funding Program (NDFP) for patients with DLBCL
on three different dates: Jan 10, 2001 (for 60–80 years old),
April 2, 2001 (for ≥80 years old), and July 1, 2004 (for all
ages). A historical cohort design was used to compare the
outcomes of patients receiving CHOP before rituximab
approval (CHOP group) with the outcomes of patients
receiving RCHOP after rituximab approval (RCHOP
group). The last follow-up date was March 31st, 2009.
The RCHOP group included patients who received
their first dose of rituximab as first-line treatment for
DLBCL from the date of rituximab approval for each age
group to December 31st, 2007. The control patients (i.e.,
CHOP group) received CHOP-based chemotherapy as
first-line treatment from January 1, 1997 to the date of
rituximab approval for each age group, and had no evi-
dence of receiving rituximab. All patients were required
to have an Ontario Cancer Registry (OCR) record of
new DLBCL diagnosis within six months prior to and up
to 30 days after their first RCHOP or CHOP treatment,
and those with missing data on histological diagnosis,
Ontario Health Insurance Plan (OHIP) number, or sex
were excluded. Furthermore, patients with a previous
diagnosis of HIV infection any time prior to their first
DLBCL diagnosis or lymphoma more than a year prior
to their first DLBCL diagnosis (defined as ICD-9 hist-
ology codes: 9590–9769) were excluded. Further details
are reported elsewhere [8].
Outcomes
The medical resources included in the cost analysis are
listed in Table S1 (see Additional file 1: Table S1). Only
direct medical costs were included, and all costs were con-
verted to 2009 Canadian dollars. The total direct medical
costs for each patient in each study arm were estimated as
the sum of all cost categories. Analyses of total health care
costs can be challenging because patient data are often
censored due to the brief nature of the follow-up. Censor-
ing arises because of the inability to follow all patients
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priately adjusting for censoring, severely biased estimates
of the mean total costs can arise. We applied the Inverse
Probability Weighting (IPW) nonparametric method to
adjust for censoring in our cost data [18]. This method ac-
counts for censoring by weighting uncensored costs by
the inverse probability of inclusion. To do this, the study
period is often partitioned and the total observed cost in
each time interval is divided by the probability of not be-
ing censored at the beginning of the interval to arrive at
the adjusted costs for each interval. Mean cost is then esti-
mated by summing the totals across all intervals and then
dividing the sum by the sample size. In our study, observa-
tion time was partitioned and interval boundaries were
chosen to coincide with censoring times. Weights were
constructed separately for each treatment group, and 3-
year and 5-year costs were estimated.
Overall survival was estimated using the Kaplan-Meier
method for each cohort. Survival was defined as the time
from diagnosis to date of death from any cause or the end
of the study timeframe. To estimate mean survival time,
the survival data were partitioned the same way as the
cost data. Mean 3-year and 5-year survival times were de-
termined using the same IPW methodology. Discounting
was applied at 3% per year to both life years and costs.
The impacts of patient age and study timeframe (3 vs.
5 years) on costs and survival were examined. These
restricted time points were chosen such that the stand-
ard errors of the survival estimates at these time points
in each group were within reasonable limits (e.g. no lar-
ger than 5-10%) [19].
Statistical analyses
To determine the adjusted association of rituximab with
the primary outcomes, the treatment groups were first
hard-matched by age group and disease severity at date
of DLBCL diagnosis. Neither stage of disease nor Inter-
national Prognostic Index (IPI) was available in the OCR
for the years of our study. We used treatment intensity
as a proxy for severity of the disease: “low” for those
who received 3–4 cycles of chemotherapy followed by
radiation within 60 days; “high” for those who received ≥
4 cycles of chemotherapy with or without radiation, and
“unclassifiable” if two or fewer cycles were administered
or if an individual received three or four cycles without
radiation [8]. Propensity scores were then estimated for
each group and subjects were matched on the estimated
propensity to receive RCHOP versus CHOP [20]. Base-
line characteristics including sex, income quintile by
postal code of residence at date of diagnosis, Adjusted
Clinical Group (ACG) scores within three years prior to
diagnosis, and primary histological diagnosis code were
entered as independent variables in a multivariate logis-
tic regression model. RCHOP and CHOP patients weresubsequently matched (1:1) on propensity scores, with-
out replacement. Nearest neighbour matching using cali-
pers of width 0.2 standard deviations of the logit of the
propensity score was used [21]. All unmatched patients
were removed from further analysis. Standardized differ-
ences were assessed for balance in the baseline charac-
teristics of the treatment groups after propensity-score
matching [20]. A standardized difference of less than
10% in a covariate was considered to represent good
balance between treatment groups [22]. P-values were
calculated using the Wilcoxon signed rank test for
continuous variables and McNemar’s test for binary
variables.
The incremental cost-effectiveness ratios (ICERs) were
estimated by dividing the mean additional total costs by
the additional mean life-years gained associated with ri-
tuximab. The 95% confidence intervals (CIs) for the
ICERs were estimated using a non-parametric bootstrap-
ping method with 1,000 replicates. Each bootstrap iter-
ation included both the cost and survival of the matched
pair. The results for CHOP compared to RCHOP were
presented as a scatter plot on the cost-effectiveness
plane and as cost-effectiveness acceptability curves.
Results
The study consisted of 4,021 patients with DLBCL, of
whom 2,825 were in the RCHOP group and 1,196 were in
the CHOP group (Table 1). The differences between pa-
tient groups were significant (absolute standardized dif-
ference >10%) for three of the six baseline characteristics,
suggesting that treatment status was confounded by factors
prognostic of DLBCL mortality. Patients who received
RCHOP were older, and had more comorbidity and differ-
ent histology. We matched 1,099 patients in the CHOP
group (92%) to 1,099 patients who received RCHOP. There
were no significant differences in measured characteristics
between treatment groups after matching.
Mean discounted survival
Figure 1 illustrates the overall survival functions and the
number at risk by year for the two groups. The 3-year and
5-year mean survival of DLBCL patients treated with
RCHOP were 2.28 and 3.44 years, respectively, compared
with 2.16 and 3.18 years in the CHOP group (Table 2).
RCHOP was associated with a mean absolute survival gain
of approximately 1.3 months (95% CI 0.7-2.3) at three years
and 3.2 months (95% CI 1.6-4.7) at five years. Age was asso-
ciated with reductions in survival in both treatment arms in
the 3- and 5-year time frames.
Mean discounted costs
The median follow-up time was 9.7 years for the CHOP
cohort and only 3.5 years for the RCHOP cohort because
rituximab was not approved for funding until 2001 to
Table 1 Baseline characteristics of CHOP and RCHOP patients before and after age, treatment intensity and propensity
score matching
Before matching After matching
Characteristics
CHOP RCHOP
Std. diff P value
CHOP RCHOP
Std. diff P value
N = 1,196 N =2,825 N = 1,099 N = 1,099
Age at diagnosis
Mean ± SD 56 · 7 ± 16 65 · 5 ± 14 0 · 62 <·001 57 · 5 ± 16 58 · 6 ± 15 0 · 07 0 · 12
Age group
0-19 1% <1% 0 · 09 <·001 <1% <1% 0 · 00 1 · 00
20-59 56% 25% 0 · 67 53% 53% 0 · 00
60-69 19% 30% 0 · 25 20% 20% 0 · 00
70-79 20% 33% 0 · 30 21% 21% 0 · 00
80+ 5% 12% 0 · 22 6% 6% 0 · 00
Female 47% 48% 0 · 01 0 · 74 47% 48% 0 · 00 0 · 93
ACG group
0 <1% <1% 0 · 09 <·001 <1% <1% 0 · 00 0 · 96
1-3 7% 5% 0 · 10 7% 7% 0 · 02
4-6 24% 17% 0 · 18 23% 23% 0 · 00
7-9 28% 31% 0 · 05 29% 31% 0 · 03
10 + 40% 47% 0 · 16 41% 40% 0 · 02
Income quintile
1 16% 17% 0 · 02 0 · 18 16% 15% 0 · 04 0 · 62
2 20% 21% 0 · 02 19% 20% 0 · 02
3 20% 19% 0 · 02 21% 21% 0
4 24% 21% 0 · 08 23% 24% 0
5 20% 22% 0 · 06 20% 20% 0 · 01
Missing <1% <1% 0 · 02 <1% <1% 0 · 07
Severity of disease
Low 32% 30% 0 · 04 0 · 04 31% 31% 0 · 00 >0 · 99
High 54% 58% 0 · 08 56% 56% 0 · 00
Unclassifiable 15% 12% 0 · 07 13% 13% 0 · 00
Histology code
9590 16% 20% 0 · 11 <·001 16% 16% 0 · 01 0 · 92
9591 3% 3% 0 · 02 3% 2% 0 · 03
9640 80% 69% 0 · 25 79% 80% 0 · 02
9680 2% 9% 0 · 29 2% 2% 0 · 00
Median Follow-up time (years) 9 · 7 3 · 7 9 · 7 3 · 5
Std Diff, standardized difference; ACG, adjusted clinical group; Severity of disease was estimated using treatment intensity; Histology codes based on International
Classification of Disease diagnosis codes.
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horts were different in the 3-year (0% vs. 30%) and 5-year
(0.5% vs. 58%) time frames. Figure 2 illustrates the cost es-
timates before and after adjusting for censoring.
The 3-year and 5-year mean censoring-adjusted costs of
patients treated with RCHOP were $76,815 and $85,293,
respectively, and $61,394 and $68,995 in those who
received CHOP (Table 2). The incremental costs for
RCHOP were $15,421 (95% CI 10,945-20,469) over 3 yearsand $16,298 (95% CI 10,829–22,044) over 5 years. Total
costs increased with age for the RCHOP patients while
they decreased with age for CHOP, corresponding to an
increase in incremental costs with age (Table 2). Figure 3
shows the breakdown of costs by resource categories. The
main cost driver, regardless of age or treatment group,
was hospitalization. Young RCHOP patients had signifi-
cantly lower hospitalization costs than CHOP patients,
although the difference was not enough to offset the high
Figure 1 Kaplan-Meier Survival functions for Pre-era CHOP and Post-era RCHOP patients.
Table 2 3-year and 5-year cost-effectiveness results by patient age at diagnosis
Time frame Age group RCHOP CHOP Incremental (95% CI) ICER (95% CI) ($/LYG)
3 year All ages n = 1,099 n = 1,099 134,136 (71,368 - 398,400)
Mean costs $76,815 $61,394 $15,421 (10,945 - 20,469)
Mean life-years 2 28 2 16 0 11 (0 06-0 19)
<60 n = 586 n = 586 73,037 (19,839 - 326,574)
Mean costs $72,121 $61,860 $10,261 (3,680 - 16,464)
Mean life-years 2 51 2 37 0 14 (0 04-0 23)
60-79 n = 450 n = 450 302,881 (90,094 - dominated)
Mean costs $82,149 $62,328 $19,822 (13,780 - 26,693)
Mean life-years 2 04 1 98 0 07 (−0 07 - 0 20)
≥80 n = 63 n = 63 128,766 (40,809 - dominated)
Mean costs $80,456 $50,381 $30,075 (14,048 - 49,693)
Mean life-years 1 78 1 55 0 23 (−0 11 - 0 61)
5 year All ages n = 1,099 n = 1,099 61,984 (34,087 - 135,890)
Mean costs $85,293 $68,995 $16,298 (10,829 - 22,044)
Mean life-years 3 44 3 18 0 26 (0 13 - 0 39)
<60 n = 586 n = 586 31,789 (6,195 - 160,587)
Mean costs $77,453 $68,281 $9,172 (1,765 - 16,252)
Mean life-years 3 88 3 60 0 29 (0 09 - 0 47)
60-79 n = 450 n = 450 80,601 (34,420 - dominated)
Mean costs $90,818 $72,006 $18,812 (12,124 - 26,301)
Mean life-years 3 02 2 79 0 23 (−0 02 - 0 45)
≥80 n = 63 n = 63 110,071 (33,478 - dominated)
Mean costs $94,131 $54,114 $40,017 (18,077,68,826)
Mean life-years 2 46 2 10 0 36 (−0 22 - 0 98)
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; RCHOP, CHOP with rituximab; ICER, incremental cost-effectiveness ratio; CI, confidence interval.
All values discounted (at r = 3%) and censored adjusted (with Inverse Probability Weighting). All costs are in 2009 Canadian dollars.
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61,394
74,734
61,394
76,815
50,000
60,000
70,000
80,000
90,000
CHOP RCHOP
Unadjusted
censor-adjusted
68,993
77,748
68,995
85,293
50,000
60,000
70,000
80,000
90,000
CHOP RCHOP
Unadjusted
Censor-adjusted
Figure 2 The effect of adjusting for censoring in 3-year (left) and 5-year total costs (right). Matched pre-era CHOP and post-era RCHOP
patients; all ages; all values discounted.
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elderly RCHOP patients had higher hospitalization costs
than CHOP patients because hospitalization costs de-
creased with age among CHOP patients but increased
with age among RCHOP patients. The cost of rituximab
also decreased with age, and accounted for the major cost
difference between the two treatment groups, except in
the very elderly group, for whom the costs of home care
and complex continuing care surpassed that of rituximab.
Most of the costs were incurred during the first year fol-
lowing DLBCL diagnosis (Table 3).
Cost-effectiveness
The ICER for all ages was $134,136/life-year gained (LYG)
(95% CI 71,368 - 398,400) with a 3-year time horizon, and
$61,984/LYG (95% CI: 34,087 - 135,890) with a 5-year
time horizon (Table 2). This decrease over a longer time
horizon reflects the concentration of costs in the first
three years, while benefits extended into subsequent years.
This held true for all age subgroups. However, the 5-year
ICERs increased with age (Table 2), consistent with the in-
creases in incremental costs with age.
Using the 5-year cost-effectiveness acceptability curves
and assuming a willingness-to-pay threshold of $50,000/
LYG, RCHOP was cost-effective in 23% of the bootstrap
replications for all ages, 79% for the younger patients
(<60 years), 15% for the elderly (60–79 years), and 14% for
the very elderly (≥80 years) patients (Figure 4b). Assuming
a willingness-to-pay threshold of $100,000/LYG, RCHOP
was cost-effective in 90% of the replications for all ages,
96% for the younger patients, 62% for the elderly, and 47%
for the very elderly.
Discussion
Our overall results show that RCHOP for DLBCL was as-
sociated with a mean improvement in survival of approxi-
mately 3.2 months over a 5-year period but approximately$16,000 higher costs than standard CHOP chemotherapy,
with an ICER of $62 K/LYG and a high probability of
being cost-effective if the willingness-to-pay were at
least $100 K for an extra year of life. However, cost-
effectiveness decreased significantly with age, suggesting
that the use of rituximab is not as economically attractive
in the very elderly.
Our study had several strengths. First, our large
population-based analysis included very elderly patients
previously excluded from RCTs and young patients who
were not captured in other databases such as Medicare.
We also included a more comprehensive list of cost ele-
ments than previous cost-effectiveness studies [11,14],
which allowed us to analyse the cost components with
respect to age and time up to five years. Costs from this
study are not only relevant to countries with a universal
single-payer healthcare system similar to Ontario’s, but
also to systems with multiple payers in which these
healthcare costs would be distributed among private
insurers, government-sponsored insurance, and patient
out-of-pocket costs. Second, this study used administra-
tive datasets exclusively, rather than prediction models
[11-14], to address the knowledge gap on the cost-
effectiveness of rituximab for DLBCL in routine clinical
practice. The results from this evaluation provide add-
itional evidence needed to make or re-evaluate coverage
decisions to ensure medical benefits, safety, and afford-
ability of innovation. Third, we used a rigorous matching
protocol to reduce bias [20]. Finally, we applied IPW to
account for censoring in the cost and survival data. Al-
though there are guidelines for the statistical analysis of
censored cost data, few studies apply them [23].
There are several limitations to our study. First, the
OCR for the study period did not contain stage data or
full prognostic information (e.g. IPI score) for DLBCL
patients, which are clinically useful predictors of survival
outcomes that help guide treatment planning. We used
Figure 3 Total cost by cost category for patients (a) <60, (b) 60–79, and (c) ≥80 years old. All values discounted and censored adjusted.
Blue bar represents CHOP patients; light pink bar represents R-CHOP patients.
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mate the burden of co-morbid illness, and used treatment
intensity as a proxy for disease severity, but differences in
treatment practices may lead to misclassification, although
how this would bias the apparent incremental benefits
and costs of rituximab is unclear. Since RCHOP is associ-
ated with improved survival compared to CHOP, it is pos-
sible that a CHOP patient who achieved the same number
of cycles of therapy as his/her RCHOP match was actually
healthier, and hence matching on treatment intensitycould lead to estimates that might be biasing against ritux-
imab. However, we expect this selection bias, if any, to be
small. Second, outpatient prescription drug data were not
available for most patients aged <65 years. However we
expect minimal bias because we hard-matched the treat-
ment groups by age. Third, we relied predominantly on
Activity Level Reporting data to select our CHOP cohort,
and therefore did not include patients from hospitals or
clinics that did not submit data, potentially explaining the
smaller size of the CHOP cohort before matching.
Table 3 Mean cost by year and patient age at diagnosis
Mean cost
(CAD$)
Year from diagnosis
1 2 3 4 5
All Ages
CHOP 45089 10890 5415 4052 3549
RCHOP 63266 7733 5816 4343 4135
<60 yrs old
CHOP 44401 12249 5211 3633 2787
RCHOP 60007 7031 5084 2825 2507
60-79 yrs old
CHOP 46488 9678 6161 4926 4752
RCHOP 67364 8532 6254 4894 3774
≥80 yrs old
CHOP 41490 6902 1988 1699 2034
RCHOP 64310 8465 7681 8142 5533
All values discounted (at r = 3%) and censored adjusted (with Inverse
Probability Weighting). All costs are in 2009 Canadian dollars.
CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; RCHOP,
CHOP with rituximab.
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proving its representativeness. Fourth, cost and survival
benefits accumulated at a different rate in our study.
While most costs were incurred in the first years after
diagnosis, survival gains extend into later years. The ICER
estimate is very sensitive to survival benefits, and it is pos-
sible that rituximab would be more favourable if the
follow-up time was to extend beyond 5 years. Our ap-
proach measures, at best, a 5-year estimate. Finally, we did
not use a contemporaneous cohort design due to rapid ri-
tuximab uptake post-approval. In fact, only a small subset
(5-6%) of patients did not receive rituximab after 2005.
These patients could be sicker, weaker, or have other
health conditions, and using them as contemporary com-
parators could introduce unnecessary bias. With a histor-
ical cohort design, however, temporal improvement in
patient management and differential censoring are chal-
lenges. To account for differential censoring, we limited
our study time period and applied IPW to each treatment
group separately. It is possible that recent widespread ef-
forts in Ontario to shift end-of-life care from acute care
settings to home care and community care centres [24],
and to shift complex continuing care from a lighter care
residential model to active rehabilitation of more medic-
ally complex patients partially explain the higher home
care and continuing care costs we detected among our
very elderly RCHOP patients [25], but these trends were
not evident in the other age groups. Nonetheless, the costs
we reported were the actual costs observed and we feel
that our results represent valid estimates of the cost of
care of RCHOP patients in the context of contemporary
management for the period observed.Compared to other studies that used same time hori-
zons, our survival benefit from rituximab among young
patients is lower than an Italian model (1.6 vs. 2.2 months
at 3 years) [11], but it only included patients with good
prognosis [3]. Our 5-year overall survival gain for elderly
patients was similar to a study in British Columbia (BC)
(0.2 vs 0.4 year) [15], but much lower than the 1.04 years
reported in a US study that extrapolated survival data
from the European phase III GELA trial [14]. Different
modelling assumptions and extrapolation of trial data can
generate a substantial variability in outcomes, highlighting
the importance of validating findings with follow-up com-
parative effectiveness research such as this study.
While rituximab extended survival in all age groups, we
found that its major impact on healthcare resource
use was the reduction in hospitalization among pa-
tients <80 years old, especially for the youngest patients
(<60 years). For the very elderly (≥80 years), however,
RCHOP did not reduce hospitalization, while costs of
other non-cancer resources significantly increased with
age among RCHOP patients more than among CHOP pa-
tients, resulting in a high incremental cost for this age
group. This is consistent with a recent Medicare study
that reported more expensive non-chemotherapy-related
and non-cancer related care among elderly rituximab pa-
tients as a result of longer survival [26]. In our elderly ri-
tuximab patients, some of the additional costs were offset
by the reduction in hospitalization, partially explaining
our lower incremental cost than the Medicare study (4-
year: $20 K vs. Medicare $28 K) (all values converted to
2009 Canadian dollars and rounded). Also that study only
included patients >65 years old. In contrast to the Medi-
care study, our very elderly patients experienced an even
more significant increase in non-chemotherapy and non-
cancer costs, resulting in our higher incremental costs (4-
year $37 K vs. $25 K), and suggesting rituximab is not
cost-effective by standard thresholds (Medicare ICER:
$60 K/LYG vs. our ICER: $114 K/LYG). This may be re-
lated to the fact that very elderly patients who received
RCHOP had greater survival benefit than other age
groups, and continued to incur more cost-intensive med-
ical costs due to age and other conditions.
We found that real-world costs, incremental costs and
cost-effectiveness ratios are higher than in published eco-
nomic models and differ by age [11,14,15]. For example,
we did not observe lower costs in rescue therapy that
could offset the high costs of rituximab to make it a cost-
saving intervention for young patients, as projected by an
Italian model [11], or lower costs in palliative care for the
elderly patients that could significantly reduce incremental
cost, as described by the US model [14]. These models,
however, excluded key drivers of total and incremental
costs such as the costs of hospitalization and prescription
drugs. Compared to a British Columbia microsimulation,
Figure 4 Incremental cost-effectiveness ratio scatterplot and cost-effectiveness acceptability curves. (a) Top - Scatterplot for incremental
cost-effectiveness ratios (ICERs) for all ages based on bootstrapping. Each point represents the mean incremental cost and effectiveness of RCHOP
compared to CHOP. A shift of distribution of ICERs from a 3-year to a 5-year timeframe is demonstrated. (b) Bottom - 5-year cost-effectiveness
acceptability curves for different age groups. The curves represent the probability RCHOP is cost-effective compared with CHOP based on a
willingness-to-pay threshold for the ICER.
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$10 K) for young patients [15], but significantly higher for
elderly patients ($19 K vs. $8 K). That study projected a
reverse trend of incremental costs and ICER with age
($51 K/LYG for young patients and $21 K/LYG for the
elderly) than what we observed, but its cost estimates were
based on aggregated and literature-based data, and it did
not observe a relationship between non-chemotherapy
cost components and age as did our observational study.
Variations in the ICERs found in these economic analyses
are driven by different model assumptions.
Cost-effectiveness results are sensitive to study time-
frame. Since most costs were incurred within the first
years following DLBCL diagnosis, a longer study horizon
resulted in a more economically attractive assessment
because benefits extend into subsequent years. In fact, afollow-up study on the GELA trial showed that the sur-
vival benefits of the addition of rituximab to CHOP per-
sisted over a 10-year follow-up [27]. Our study’s goal
was to highlight the usefulness of providing cost-
effectiveness information alongside comparative effect-
iveness data that reflect routine clinical practice on
representative patients, so we did not extrapolate
beyond our data. Follow-up studies could examine the
cost-effectiveness of rituximab over a longer time hori-
zon and compare against findings in published models
that used standardized methods for life-time projections
of survival benefit and costs.
Conclusions
While trial data and predictive modelling remain the gold
standards for estimating clinical efficacy and costs in
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seeking real-world evidence. Our real-world cost-
effectiveness analysis demonstrates that post-market eval-
uations that reflect actual practice can produce results
that differ from trials or prediction models, but results are
sensitive to patients’ age and study timeframe. This type of
post-market analysis can help calibrate policies (e.g., to re-
evaluate decisions post-approval) and support healthcare
payers’ mandate for accountability and sustainability, and
they should become a more routine part of drug listing
appraisals, contributing to a life cycle approach to drug
evaluation. Our study also highlights the impact of appro-
priate methods to adjust for incomplete cost data and
choice of timeframe on real-world cost-effectiveness
results. These findings have important implications for es-
tablishing “coverage with evidence development” or “only
in research” funding arrangements.
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